Hookipa Pharma (NASDAQ:HOOK)‘s stock had its “buy” rating restated by SVB Leerink in a report issued on Sunday, Price Targets.com reports.
A number of other research analysts have also commented on the company. Morgan Stanley cut their target price on Hookipa Pharma from $19.00 to $18.00 and set an “overweight” rating for the company in a research note on Wednesday, August 18th. Zacks Investment Research cut shares of Hookipa Pharma from a “buy” rating to a “hold” rating in a research note on Friday, July 23rd. TheStreet downgraded shares of Hookipa Pharma from a “c-” rating to a “d” rating in a report on Wednesday, July 7th. Finally, JMP Securities reissued a “buy” rating and issued a $25.00 target price on shares of Hookipa Pharma in a research note on Friday, June 4th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, Hookipa Pharma has an average rating of “Buy” and an average target price of $20.43.
NASDAQ:HOOK opened at $6.55 on Friday. The firm’s 50-day moving average is $7.15 and its 200-day moving average is $10.89. The company has a market cap of $170.78 million, a price-to-earnings ratio of -3.21 and a beta of 1.11. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.23 and a current ratio of 4.23. Hookipa Pharma has a 52-week low of $6.01 and a 52-week high of $20.00.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Morgan Stanley increased its position in shares of Hookipa Pharma by 3,639.8% during the 2nd quarter. Morgan Stanley now owns 149,256 shares of the company’s stock worth $1,367,000 after purchasing an additional 145,265 shares in the last quarter. Wells Fargo & Company MN increased its holdings in shares of Hookipa Pharma by 306.9% during the second quarter. Wells Fargo & Company MN now owns 65,257 shares of the company’s stock worth $597,000 after buying an additional 49,221 shares in the last quarter. Woodline Partners LP raised its stake in shares of Hookipa Pharma by 32.5% in the second quarter. Woodline Partners LP now owns 901,602 shares of the company’s stock valued at $8,259,000 after acquiring an additional 221,342 shares during the last quarter. Millennium Management LLC bought a new position in shares of Hookipa Pharma in the second quarter valued at approximately $3,553,000. Finally, UBS Asset Management Americas Inc. acquired a new position in shares of Hookipa Pharma in the 2nd quarter worth approximately $3,034,000. 47.97% of the stock is currently owned by institutional investors and hedge funds.
Hookipa Pharma Company Profile
HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.
Recommended Story: How to calculate the annual rate of depreciation
Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.